PCIP

The AMA-Physician Consortium for Performance Improvement (PCIP) is a national, physician-led program dedicated to enhancing quality and patient safety. PCIP identifies and develops evidence-based clinical performance measures and measurement resources that enhance the quality of patient care and foster accountability. PCIP aims to promote the implementation of effective and relevant clincial performance improvement activities, and to advance the science of clinical peformance measurement and improvement. Recently, the Agency for Healthcare Research and Quality published information regarding new PCIP measures for coronary artery disease. We thought you might find this information helpful to your practice.

Measure Summaries

Physician Consortium for Performance Improvement®

• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period and with results of an evaluation of level of activity AND an evaluation of presence or absence of anginal symptoms, with appropriate management of anginal symptoms (evaluation of level of activity and symptoms includes no report of anginal symptoms OR evaluation of level of activity and symptoms includes report of anginal symptoms and a plan of care is documented to achieve control of anginal symptoms).


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period for whom there are documented results of an evaluation of level of activity AND an evaluation of presence or absence of anginal symptoms in the medical record. This updates a previously published measure summary.


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes or a current of prior left ventricular ejection fraction (LVEF) less than 40% who were prescribed angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy. This updates a previously published measure summary.


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have prior myocardial infarction (MI) or a current or prior left ventricular ejection fraction (LVEF) less than 40% who were prescribed beta-blocker therapy. This updates a previously published measure summary.


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who have a LDL-C result less than 100 mg/dL OR patients who have a LDL-C result greater than or equal to 100 mg/dL and have a documented plan of care to achieve LDL-C less than 100 mg/dL, including at a minimum the prescription of a statin.


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who were prescribed aspirin or clopidogrel. This updates a previously published measure summary.


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who were screened for tobacco use AND who received tobacco cessation counseling intervention if identified as a tobacco user.


• Chronic stable coronary artery disease: percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period with a blood pressure less than 140/90 mm Hg OR patients with a blood pressure greater than or equal to 140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit.


• Chronic stable coronary artery disease: percentage of patients in an outpatient clinical practice who have had a qualifying event during the previous 12 months who have been referred to an outpatient cardiac rehabilitation (CR) program.